SUPN FY 2012 Earnings — Supernus Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

SUPNSupernus Pharmaceuticals, Inc.

$3B

FY 2012 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$1M+84.3% YoY

Gross Profit

$1M100.0% margin

Operating Income

-$42M-2849.3% margin

Net Income

-$46M-3127.3% margin

EPS (Diluted)

$-2.65

Cash Flow

Operating Cash Flow

-$47M

Free Cash Flow

-$48M

Stock-Based Comp.

$443,000

Balance Sheet

Total Assets

$94M

Total Liabilities

$36M

Stockholders' Equity

$58M

Cash & Equivalents

$89M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$1M	$803,000	+84.3%
Gross Profit	$1M	$803,000	+84.3%
Operating Income	-$42M	-$38M	-11.7%
Net Income	-$46M	$56M	-182.6%